Tenaya Therapeutics Q1 2024 GAAP EPS $(0.40) Beats $(0.42) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tenaya Therapeutics reported Q1 2024 GAAP EPS of $(0.40), surpassing the analyst consensus estimate of $(0.42) by 4.76 percent.
May 14, 2024 | 8:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tenaya Therapeutics reported a smaller-than-expected quarterly loss, beating analyst estimates.
Beating earnings estimates typically leads to positive investor sentiment and can cause a short-term increase in stock price. The beat, although modest, indicates better-than-expected financial health and performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100